CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES

CCTN - 避孕临床试验网络 - 女性站点

• 批准号: 10329659
• 负责人: LIVIA WAN
• 金额: $ 3万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-19 至 2021-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10329659
• 关键词: Acetates; Clinical; Clinical Practice Guideline; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contractor; Contracts; Dose; Enrollment; Equipment; Estrogens; Female; Goals; Good Clinical Practice; Government; Hemorrhage; Human Resources; Institutional Review Boards; International; Methods; Modification; Monitor; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; Progestins; Protocols documentation; Records; Regimen; Regulation; Resolution; Risk; Safety; Services; Site; Time; Uterine Fibroids; Woman; Work; contraceptive efficacy; emergency contraception; follow-up; pharmacokinetics and pharmacodynamics; progesterone receptor A; recruit; side effect; symposium; venous thromboembolism

There is a demand for estrogen-free contraception in order to reduce the risk of venous thromboembolism (VTE), particularly for obese women. A new oral contraceptive agent consisting of a progesterone receptor modulator, which does not affect endogenous estrogen levels, has been developed. Ulipristal acetate (UPA) has been used in a single high dose for emergency contraception and has been used continuously for up to six months for treatment of uterine fibroids. Low dose continuous usage of oral UPA is anticipated to inhibit ovulation and provide an estrogen free, bleed free method of contraception.

为了减少静脉血栓的风险，需要无雌激素避孕。 血栓栓塞（VTE），特别是肥胖女性。一种新的口服避孕药 由孕酮受体调节剂组成，不影响内源性雌激素 水平，已经发展。醋酸乌利司他（UPA）已用于单次高剂量， 紧急避孕，并已连续使用长达六个月，以治疗 子宫肌瘤低剂量连续口服UPA预期会抑制排卵， 提供一种无雌激素、无出血的避孕方法。